G1 Therapeutics Announces Expansion of Development Programs


G1 Therapeutics announced today the expansion of its pipeline of novel cancer therapies with initiation of three development programs in breast cancer. G1 is enrolling a Phase 2 study of its intravenous CDK4/6 inhibitor trilaciclib for the treatment of triple-negative breast cancer (TNBC), and a Phase 1b/2a study of its oral CDK4/6 inhibitor G1T38 for the treatment of ER+, HER2-... Continue

Medicines Company Announces Top-Line Inclisiran Data


The Medicines Company today announced positive top-line results from the interim analysis with Day 180 follow-up for all 501 patients enrolled in the ongoing ORION-1 Phase 2 study of inclisiran, its investigational, first-in-class PCSK9 synthesis inhibitor Continue

Auven Announces Asset Sale


Auven Therapeutics announces closing of sale of Ocular Technologies Sarl, holding entity for Seciera for treatment of dry eye disease. Continue

Innocrin Announces Preliminary Results


Innocrin Pharmaceuticals, a clinical stage company focused on the development of the oral selective CYP17-lyase/androgen receptor (AR) inhibitor, seviteronel, announced today that clinical results from the ongoing Clarity (CYP17 Lyase and Androgen Receptor Inhibitor Treatment study) were presented at the 39th annual San Antonio Breast Cancer Symposium. Continue